Find Academic Supervisors

Jinhong Meng is a Senior Research Fellow at the Department of Genetics & Genomic Medicine, University College London (UCL), focusing on neuromuscular disorders and gene therapy. He earned his PhD and Bachelor’s degrees from the Fourth Military Medical University. Education: Doctor of Philosophy, Fourth Military Medical University (2000) Bachelor, Fourth Military Medical University (1995) Research Interests: Jinhong Meng’s work centers on Duchenne Muscular Dystrophy (DMD), Spinal Muscular Atrophy (SMA), and gene therapy techniques including CRISPR, lentiviral vectors, and antisense oligonucleotides. His studies explore immune responses to dystrophin, vascular defects in SMA, and dystrophin correction via viral and non-viral delivery systems. Publication Trends: Over the past eight years, Jinhong Meng has published extensively on DMD and SMA, with a focus on gene editing, dystrophin restoration, and cellular therapies. His collaborative work spans lentiviral vectors, foamy virus transduction, and necroptosis mechanisms in muscle degeneration. Labs & Collaborations: He works within UCL’s Genetics & Genomic Medicine Department, collaborating on projects involving dystrophic muscle engraftment, circadian signaling, and RNA editing for genetic mutations.

• Clinical sciences
• Neurosciences
• Medical physiology
• +2 more

Dr. Celine Cano is a research-focused academic at Newcastle University's Faculty of Medical Sciences within the School of Pharmacy and Biomedical Sciences, with a distinguished career spanning nearly two decades in cancer drug discovery and medicinal chemistry. Her work centers on developing targeted therapies, particularly kinase inhibitors and MDM2-p53 interaction antagonists, with significant contributions to understanding molecular mechanisms in oncology. Her research interests encompass cancer drug discovery , medicinal chemistry , and kinase inhibitor development , with specialized expertise in covalent drug design, fragment-based screening, and structural optimization of anticancer agents. Dr. Cano has pioneered work on MDM2-p53 inhibitors, ERK5 modulators, and PROTAC technologies, focusing on enhancing therapeutic indices while minimizing toxicity through precise molecular engineering. Analysis of her 15 most recent publications (2020-2024) reveals a dominant focus on targeted cancer therapies , particularly small-molecule antagonists of protein-protein interactions (MDM2-p53) and kinase inhibitors (ERK5, Nek2, NIK). Her work demonstrates consistent innovation in covalent drug design , pharmacokinetic optimization , and structural biology approaches to overcome resistance mechanisms. Notable trends include the development of differentiated pharmacokinetic profiles in next-generation MDM2 antagonists and sophisticated linker strategies for PROTACs. Dr. Cano maintains extensive collaborative networks across Newcastle University's cancer research ecosystem, particularly with groups led by Professors Ian Hardcastle, Bernard Golding, and Steve Wedge. Her research has been instrumental in advancing multiple drug candidates through preclinical development, with several publications describing compounds that have progressed to therapeutic evaluation.

• Cancer Drug Discovery
• Medicinal Chemistry
• Kinase Inhibitors
• +4 more

Ted Hupp is Chair of Cancer Research and Professor of Cancer Research at the University of Edinburgh's Institute of Genetics and Cancer, where he leads the Edinburgh Cancer Research Centre. His laboratory focuses on developing next-generation technologies for drug discovery in cancer, with particular emphasis on cancers of unmet clinical need including oesophageal adenocarcinoma and sarcomas. Dr. Hupp's research interests center on understanding cancer progression pathways, particularly those involving p53 mutation, which is one of the most common genetic changes in cancer development. His lab employs biophysical, biochemical, and proteomic approaches to develop novel molecular insights into clinically relevant cancer progression pathways. His work spans three main research programs: drugging protein-protein interactions to activate the p53 tumour suppressor, investigating the secretory pathway as a driver in oesophageal cancer, and developing immunotherapeutics, monoclonal antibodies, and vaccinology platforms. Analysis of his recent publications reveals a strong focus on proteogenomics, protein science, and translational applications. His work increasingly integrates canine models for comparative medicine, proteomic approaches to understand protein synthesis dynamics, and novel antibody development for cancer therapeutics. The research shows a clear trajectory toward personalized cancer immunotherapies and vaccine development based on neoantigen landscapes. Professor Hupp has successfully secured funding from major organizations including BBSRC, Medical Research Scotland, The Technology Strategy Board, British Council, European Union Development Fund, Wellcome Trust, and Cancer Research UK. His current projects include optimization of synthetic antibody libraries, selection and characterization of anti-peptide synthetic antibodies, CRISPR-based genome-wide approaches for identifying vulnerabilities in canine oral melanoma, and the KATY project focused on clinical knowledge systems. He advises multiple PhD students including Kamila Pawlicka, Estefania Esposito, Vanessza Fentor, Sinem Gul, and Mishal Tariq. His research group collaborates extensively with scientists across the University of Edinburgh, Cambridge University, Masaryk Cancer Institute in Brno, and the Indian Institute for Science in Bangalore. The lab maintains expertise in protein science, post-translational modifications, phage antibody libraries, RNA editing, p53 pathway science, and proteogenomics.

• Cancer Research
• p53 Pathway Science
• Protein-Protein Interactions
• +7 more

Dr. Karim Bennaceur is a researcher at Newcastle University , focusing on the intersection of immunology and cardiovascular medicine. His work explores immune cell dynamics, telomerase mechanisms, and inflammatory pathways in myocardial infarction and ischemic injury. Key collaborations include studies on TGF-β1 mimics, telomerase activation, and CMV-seropositivity impacts on cardiac recovery. Research spans immunology , cardiology , and molecular biology , with a focus on lymphocyte kinetics, chemokine signaling, and telomere maintenance. His publications highlight clinical trials in elderly patients and mechanistic insights into T cell proliferation and atherosclerosis.

• Immunology
• Cardiology
• Molecular Biology
• +2 more

Professor John Lunec, based at Newcastle University 's Faculty of Medical Sciences , is a leading researcher in Molecular Oncology with over 30 years of publications focusing on the p53 tumor suppressor pathway and its interactions with oncogenic proteins like MDM2 . His work spans Cancer Therapeutics Development Genomic Instability in Tumors Drug Resistance Mechanisms RNA Splicing and Retrotransposon Biology Current research emphasizes MDM2-p53 interaction inhibitors for hematologic malignancies and sarcomas, with recent breakthroughs in Siremadlin and ASTX295 drug development Identification of SF3B1 resistance biomarkers Combination strategies with PARP and WEE1 inhibitors Key collaborations exist with Professor Nicola Curtin , Professor Deborah Tweddle , and Professor Herbie Newell , with funding evident through multiple clinical trials and laboratory studies. His work has significantly impacted neuroblastoma and ovarian cancer research, establishing frameworks for Drug sensitivity assays Genotype-phenotype correlations Translational medicine applications

• Molecular Oncology
• Cancer Therapeutics
• Genetic Abnormalities in Tumors
• +3 more

Professor Richard Edmondson is affiliated with Newcastle University, focusing on ovarian and endometrial cancer research. His work emphasizes molecular profiling, DNA repair mechanisms, and tumor heterogeneity. Research interests include: DNA damage repair pathways in ovarian cancer Molecular characterization of tumor-ascites relationships Circulating tumor cell detection Drug sensitivity assays and functional heterogeneity analysis p53 pathway biomarkers in endometrial cancer Publications highlight trends in precision oncology, combining genomic analysis with imaging flow cytometry for diagnostic applications. Collaborators include Dr Aiste McCormick and Dr Rachel O'Donnell. Key contributions: Development of ovarian cancer cell line models Investigations into MDM2-p53 antagonists and chemotherapy synergy Studies on platinum resistance mechanisms

• Ovarian Cancer
• DNA Damage Repair
• Molecular Profiling
• +7 more

Dr. Emma Haagensen is a researcher at Newcastle University, primarily collaborating on biomedical studies in oncology and medical education. Her work spans translational research in cancer therapies, including MEK/PI3K inhibitors and TRAIL-based treatments, and educational studies evaluating active learning strategies and study support systems in medical curricula. She frequently collaborates with Prof. Herbie Newell, Prof. Kenneth Dalgarno, and Dr. Gary Beale, among others. Research Interests: Oncology: Focus on molecular mechanisms of cancer progression (osteosarcoma, prostate cancer, colorectal cancer) and targeted therapies. Molecular Biology: Investigates replication licensing, cell cycle regulation, and hypoxia signaling. Medical Education: Analyzes active learning strategies and digital education adaptations during the pandemic. Publication Trends: Her recent work emphasizes transnational education studies and pre-clinical cancer research, with historical contributions to drug synergy models and DNA replication dynamics.

• Oncology
• Molecular Biology
• Medical Education
• +3 more

Ashley Kamimae-Lanning is a Senior Research Fellow at the MRC Weatherall Institute of Molecular Medicine (WIMM), University of Oxford, within the Radcliffe Department of Medicine. Her research focuses on cellular defense mechanisms against aldehydes, particularly their effects on hematopoietic stem cells and DNA repair pathways in Fanconi anemia. She completed her PhD at Oregon Health & Science University under Peter Kurre, investigating prenatal defects in hematopoietic stem cells. Her work bridges developmental biology and genetics, exploring how endogenous aldehydes contribute to DNA damage and hematopoietic failure. Collaborations include work with Dr. Daniel Marks on metabolic programming of fetal liver hematopoiesis and the Patel Lab on 'two-tier protection' mechanisms against genotoxic aldehydes. Recent studies highlight aldehyde-induced stem cell aging and carcinogenesis risks in FA patients. Key publications include groundbreaking work on formaldehyde toxicity in hematopoietic stem cells and dual aldehyde clearance systems in mice/humans. She advises DPhil students like Xinran Huang and received the Sir Andrew McMichael Medal for mentorship. Her lab integrates molecular, cellular, and genetic approaches to understand metabolic-DNA repair interactions in disease contexts.

• Hematology
• DNA Repair
• Cell Biology
• +4 more

Professor Heike Laman is the Head of the Department of Pathology and Professor of Cellular and Molecular Biology at the University of Cambridge , leading research on ubiquitin ligases and their roles in disease. Her work bridges molecular mechanisms to therapeutic applications, focusing on cancer, neurodegeneration, and protein homeostasis. Current affiliation: Department of Pathology, School of the Biological Sciences Resident at Clare College since 2014 (Fellow and Graduate Admissions Tutor) Research Interests: Ubiquitin ligases orchestrate diverse cellular signals beyond protein degradation, influencing activity, localization, and interactions. Key areas include: Cancer: Investigating SCF-Fbxw7 networks in epithelial cancers and cyclin E1 accumulation Neurodegeneration: Fbxo7's role in Parkinson's disease and dopaminergic neuron survival Therapeutic Innovation: Developing PROTACs and nanobodies to target ubiquitin ligases Publication Trends: Recent work spans ubiquitin signaling in cancer metabolism, neuroprotective pathways in Parkinson's, and structure-based design of degraders. Collaborations with AstraZeneca and academic experts highlight translational focus. Scientific Awards: Recognized for academic leadership, including election to Clare College Fellowship (2014) and early career Imperial Cancer Research Fund Fellowship. Advising: Mentors PhD students in projects on ubiquitin ligases, Parkinson's, cancer metabolism, and targeted protein degradation, with lab members working in 3D organoids , mouse models , and hiPSC-derived systems . Labs & Teams: Based at the Department of Pathology (Downing Site, Cambridge), the lab collaborates across Genetics , Pharmacology , and Clinical Neurosciences , with access to the Microscopy Bioscience Platform and Cambridge Stem Cell Institute .

• Ubiquitin ligases
• Cell cycle regulation
• Cancer biology
• +5 more

Dr. Emilie Hollville is a Lecturer at the School of Medicine, Medical Sciences and Nutrition, University of Aberdeen (since 2022), with research focusing on programmed cell death (apoptosis), mitochondrial quality control, and their roles in neurodegenerative disorders and aging. Her work bridges molecular biology, neuroscience, and biomedical sciences. PhD (2009) - Université Paris-Saclay, France MSc (2004) - Université Paris-Saclay, France BSc (2003) - Université de Versailles, France Research interests include: Understanding molecular pathways in neuronal maturation and lifelong survival Role of ubiquitin ligases and apoptosis regulators in neurodevelopment Investigating mitochondrial dysfunction in age-related neurodegenerative diseases (e.g., Parkinson’s) Her publications span topics like miR-29 in aging and neurodegeneration, apoptosis regulation in neurons, and mitophagy mechanisms. She has received the Academy of Medical Sciences Springboard award (2024/26). Supervision includes: Current PhD Students: Paola Muscolino, Sandra Maria Sajan Undergraduate Students: James O'Neill (Summer 2024), Iida Holappa, Jake Bell, Dana Zlateva (Honours 2024) Grants: Royal Society Research Grant (2023/24) UKRI BBSRC EASTBIO PhD Studentship (2023/27) Development Trust SCIO PhD Studentship (2023/27) Laboratory affiliations: Institute of Medical Sciences, School of Medicine, Medical Sciences and Nutrition, and the Laboratory Sustainability Working Group (LABSUS).

• Programmed Cell Death
• Apoptosis
• Neuroscience
• +7 more

Ali Tavassoli is a Professor of Chemical Biology at the University of Southampton's School of Chemistry and serves as Chief Scientific Officer at Curve Therapeutics, a VC-backed spin-out from his lab. He leads an interdisciplinary team focused on developing chemical tools to elucidate protein-protein interactions and advance therapeutic discovery. His research bridges synthetic chemistry and biology, with applications in cancer and metabolic disease. Tavassoli holds RSC Fellow status and has led roles in the Royal Society of Chemistry's Chemical Biology divisions. Education & Career: BSc Chemistry, University of Bristol PhD in Synthetic Organic Chemistry, University of Reading Postdoctoral Fellowships: University of Sussex and Penn State University Joined University of Southampton as Lecturer in 2006, promoted to Reader (2011) and Professor (2015) Research Interests: Chemical biology approaches to target protein interactions, hypoxia signaling in cancer, cyclic peptide therapeutics, and synthetic organic chemistry. His work combines molecular design with biological validation to address unmet clinical needs. Key Projects: MRC-funded studies on hypoxia-driven drug discovery EPSRC project on semi-biotic immune systems Cancer Research UK grants for HIF pathway inhibitors Awards: European Young Chemist Medal (2008) RSC Protein & Peptide Science Award (2017) European Peptide Society's Leonidas Zervas Award (2020) Professional Activities: Editorial board member for RSC Chemical Biology , former Chair of RSC Chemical Biology divisions, and inventor of SICLOPPS screening technology. His lab actively collaborates with industry and academia to translate discoveries into therapies.

• Chemical Biology
• Drug Discovery
• Protein-Protein Interactions
• +3 more

Professor Tracy Warr is a leading neuro-oncology researcher at the University of Wolverhampton's Research Institute in Healthcare Science, with over 25 years of experience in experimental brain tumour research. Previously at University College London's Institute of Neurology, she established a research programme focused on glioma treatment outcomes since 2009. Her work spans genomic/epigenetic analysis, metabolic therapies, and tumour immunosuppression. PhD, University of Wales Swansea (1991) BSc, University of Leeds (1986) Research Themes: Therapeutic target validation in paediatric/adult gliomas Metabolic dysregulation and repositioned drugs Epigenetic mechanisms in brain metastases Tumour-mediated immunosuppression in GBM Pre-clinical model development Dietary modulation of cancer progression Publication Trends: Recent work focuses on non-coding RNA methylation patterns in metastatic breast cancer, hexokinase 2's epigenetic regulation in glioblastoma, and arginine biosynthesis pathway inactivation in paediatric high-grade gliomas. Earlier studies explored PDE1C's role in tumour proliferation, flavonoid effects on invasion, and p53 dynamics in chromosomal instability. Scientific Recognition: Honorary Professor, Third Military Medical University (2012) Advising & Grants: Supervised numerous PhD projects on topics like metformin therapy, miRNA roles in angiogenesis, and secretomic analysis of GBM immunosuppression. Current research funded by grants including "Unravelling T cell immunosuppression" (Headcase Cancer Trust) and "Role of miR-133a" (Royal Wolverhampton NHS Trust).

• Neuro-oncology
• Genomic and epigenetic profiling
• Metabolic therapies for gliomas
• +5 more

Claire Bastie is an Associate Professor (Teaching Focussed) in Metabolic Biochemistry at Warwick Medical School, University of Warwick, within the Department of Biomedical Sciences. She earned her Ph.D. from INSERM's Centre of Biochemistry at Nice-Sophia-Antipolis (France), followed by postdoctoral training and a Research Instructor position at the State University of New York. She established her independent research lab at Albert Einstein College of Medicine in New York in 2010 with NIH funding, maintaining a joint appointment with Warwick Medical School from 2011-2015 before relocating permanently to Warwick. Her research investigates nutrient sensing pathways in metabolic diseases with three primary foci: Fyn tyrosine kinase regulation of adipose tissue biology in obesity Maternal-fetal metabolic signaling in pregnancies complicated by obesity/diabetes Autophagy and energy homeostasis in diabetes pathogenesis Publications demonstrate consistent emphasis on molecular mechanisms of diabetes, spanning basic kinase signaling (Fyn/AMPK), clinical studies on glycemic control technologies, and placental biology. Recent work highlights extracellular vesicles in gestational disorders and diabetic kidney disease mechanisms. Research funding includes: Medical and Life Sciences Research Fund (2021): Hyaluronic acid hydrogels for breast reconstruction fat graft survival Historic NIH support for lab establishment at Albert Einstein College of Medicine She leads the Nutrient Sensing Laboratory investigating metabolic cross-talk between tissues, with active projects on adipose plasticity and gestational diabetes pathophysiology.

• Metabolic Biochemistry
• Nutrient Sensing Pathways
• Obesity
• +3 more

Andrea Mohr is a Senior Lecturer at the University of Essex, School of Life Sciences. Her research focuses on cellular crosstalk in the tumor microenvironment and metastasis formation, particularly involving mesenchymal stem cells (MSCs). She holds a PhD from the University of Hannover (2000) and has held academic roles since, including Senior Research Officer at the University of Essex and Senior Scientist at the National University of Ireland, Galway. She currently directs the MSc Cancer Biology program at Essex. Her qualifications include a PhD in Cancer Biology and extensive post-doctoral experience. Research interests span TRAIL signaling, stem cell therapy, and metastatic mechanisms. Recent work explores biohybrid microrobots for targeted cancer treatment and the role of Fas signaling in pancreatic cancer progression. Publications highlight collaborations in nanotechnology, virology, and drug repurposing, with a focus on translating stem cell-based therapies. Grants and funding details are not explicitly listed, but her work suggests involvement in interdisciplinary cancer research projects.

• Cancer Biology
• Cellular Crosstalk
• Metastasis Formation
• +3 more

Jean A Quinn is a Technical Research and Teaching Specialist at the University of Glasgow , affiliated with the School of Cancer Sciences . Her work focuses on colorectal cancer , breast cancer , and skin carcinogenesis , particularly examining molecular mechanisms in tumor progression and microenvironment interactions. Key research themes include prognostic biomarker development , signal transduction pathways (NF-κB, STAT3, AKT), and tumor-stromal interactions . Publications highlight trends in molecular oncology , translational research , and preclinical models . Her recent studies explore multifactorial biomarker validation (e.g., TAK1, IL6/IL6R, S100A2) and hypoxia-associated pathways in breast cancer. Scientific Awards include the Bowel Cancer UK grant (2023-2024) for metastatic stratification biomarker development . Collaborations span institutions like Newcastle University, Strathclyde Technology & Innovation Centre, and British Society for Investigative Dermatology. Her expertise bridges transgenic mouse models , immunohistochemistry , and clinical data integration .

• Colorectal Cancer
• Breast Cancer
• Tumor Microenvironment
• +3 more